BIOX — Bioceres Crop Solutions Corp.

Summary of Bioceres Crop Solutions Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenues: $77.5 million, a 17% decline year-over-year.
• Gross Profit: $36.2 million, a slight decrease of 3% year-over-year, with gross margin expanding to 47% from 40%.
• Adjusted EBITDA: $13.6 million, a 61% increase compared to $8.5 million in Q1 2025.
• Financial Debt: Reduced to $242.5 million from $260.2 million in the previous quarter.
• Net Debt to Adjusted EBITDA Ratio: Improved to 6.8x.

2. Strategic Updates and Business Highlights:

• Transitioning to a more scalable and capital-efficient seed business model, reducing lower-margin sales.
• Significant improvements in SG&A costs, achieving 50% of the targeted $10 million to $12 million annualized savings in just one quarter.
• Focus on improving revenue quality, protecting margins, and maintaining operational discipline.
• Positive developments in the Crop Nutrition segment, with higher biostimulant sales in Argentina and Brazil.

3. Forward Guidance and Outlook:

• Continued expectation of revenue decline in the Seed and Integrated Products segment due to the unwinding of the HB4 downstream program for at least two more quarters.
• Commitment to maintaining gross margins above 40% and targeting profitability above 20% of adjusted EBITDA over sales.
• Anticipation of improved sales timing and recovery in Argentina post-election, which may stabilize demand.

4. Bad News, Challenges, or Points of Concern:

• Decline in revenues primarily driven by sluggish demand in Argentina and a significant drop in Crop Protection and Seed revenues.
• Ongoing disputes with noteholders regarding secured convertible and nonconvertible notes, leading to reclassification of debt and potential financial strain.
• Competitive pricing pressures in the Crop Nutrition segment, particularly in fertilizers, affecting margins.

5. Notable Q&A Insights:

• Discussion on potential for increased U.S. imports of agricultural inputs from Argentina post-election, which could benefit Bioceres.
• Clarification that while they expect sales of biopesticides in Europe to improve, current contributions are limited, with most growth seen in Latin America.
• Management emphasized their focus on maintaining financial flexibility and disciplined capital allocation amidst a complex operating environment.

Overall, while Bioceres faces challenges with declining revenues and competitive pressures, strategic initiatives and cost management efforts are yielding positive results in profitability and operational efficiency.